[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355744-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355744-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","advancements-in-the-manufacturing-routes-for-the-synthesis-of-marketed-parp-inhibitors","Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors","","PARP inhibitors play a central role in treating multiple cancers, especially ovarian and breast cancer. Seven marketed PARP inhibitors—olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, pamiparib, and senaparib—are reviewed with emphasis on their manufacturing routes reported in the literature since 2017. The review traces a shift from step-intensive medicinal chemistry syntheses to more streamlined, industrially viable processes, highlighting key transformations and improved efficiency and scalability.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/advancements-in-the-manufacturing-routes-for-the-synthesis-of-marketed-parp-inhibitors/355744/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/advancements-in-the-manufacturing-routes-for-the-synthesis-of-marketed-parp-inhibitors/355744.png","ImageObject",300,407,{"name":42,"@type":43},"Cart","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-12","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How many marketed PARP inhibitors are discussed, and which ones are named?","Question",{"text":63,"@type":64},"Seven marketed PARP inhibitors are named: olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, pamiparib, and senaparib.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What change in synthetic strategy is highlighted over the past decade?",{"text":68,"@type":64},"Synthetic strategies have moved from step-intensive medicinal chemistry routes toward more streamlined, industrially viable processes.",{"name":70,"@type":61,"acceptedAnswer":71},"Which key chemical transformations are described as part of modern manufacturing approaches?",{"text":72,"@type":64},"The review highlights transformations such as amide bond formation, C–H activation, carbopalladation, heterocycle construction, and stereocontrolled cyclisation.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355744,1790242843,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},18829141979164,"https://eur-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","RSC Advances  \nREVIEW  \nPublished on 21 May 2026 Licensed under CC-BY-NC 4.0  \nCite this: RSC Adv., 2026, 16, 27593  \nReceived 10th April 2026  \nAccepted 6th May 2026  \nDOI: 10.1039/d6ra03016e[rsc.li/rsc-advances](rsc.li/rsc-advances)  \nAdvancements in the manufacturing routes for the synthesis of marketed PARP inhibitors  \nDhurgam Rani,ab Magdalena Plebanskib and Tanmay Chatterjee  *a  \nThe signiﬁcant role of PARP inhibitors in the treatment of various cancers, especially ovarian and breast cancer, is very well established. To date, seven PARP inhibitors have received marketing approval, namely, olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, pamiparib and senaparib, in various countries. This article reviews the manufacturing routes for the synthesis of these marketed drugs reported in the literature since 2017. Over the past decade, synthetic strategies for PARP inhibitors have transitioned from step-intensive medicinal chemistry synthesis routes to more streamlined, industrially viable processes. These modern approaches integrate key transformations, such as amide bond formation, C–H activation, carbopalladation, heterocycle construction, and stereocontrolled cyclisation, enabling improved eﬃciencyand scalability. In parallel, the incorporation of green chemistry principles, particularly in one of the manufacturing routes of olaparib, has led to more sustainable process development.  \n\n| aDepartment of Chemistry, Birla Institute of Technology and Science, Pilani (BITS Pilani), Hyderabad Campus, Jawahar Nagar, Kapra Mandal, Hyderabad, 500078, India. E-mail: [tanmay@hyderabad.bits-pilani.ac.in](tanmay@hyderabad.bits-pilani.ac.in) | bSchool of\u003Cbr>Australia | Health and Biomedical Sciences, RMIT University, Melbourne, 3083, |\n| --- | --- | --- |\n\nDhurgam Rani completed her B. Pharmacy from RBVRR Women's College of Pharmacy, Hyderabad, in 2022, building a strong foundation in pharmaceutical sciences and research. She further pursued her M. Pharmacy in Medicinal Chemistry at NIPER Hyderabad, India, where she graduated with distinction and was awarded a Gold Medal for academic excellence in 2024.  \nCurrently, she is pursuing her PhD through the BITS–RMIT  \nJoint PhD Program. Her research focuses on the design and development of novel PARP inhibitors for the treatment of ovarian cancer, integrating medicinal chemistry, molecular biology, and advanced drug discovery approaches for improved therapeutic outcomes.  \nMagdalena Plebanski  \nMagdalena Plebanski is an immunologist. Her group integrates immunology, nanotechnology, and translational science to develop innovative diagnostics, vaccines and therapies. She completed her PhD atthe University of Bristol and postdoctoral studies at the University of Oxford, UK, where she pioneered work on immunosuppression and vaccine design.  \nShe subsequently held senior research and leadership roles at  \nthe Burnet Institute and Monash University before joining RMIT University, where she is now a Distinguished Professor, and Director of the Biomedical & Health Innovation Enabling Impact Platform and the Accelerator for Translational Research and Clinical Trials (ATRACT) Centre. Her research currently focuses on immune suppression, cancer immunotherapy and diagnostic and prognostic biomarkers in ovarian cancer. She has published over 250 peer-reviewed papers, has an H-index of 70, and is a top 0.5% highly cited scholar. A number of her 60 patents across multiple patent families on vaccines and prognostic biomarker technologies progressed to clinical trials. She has received numerous international honours, for example, the Howard Hughes International Scholar (HHMI) Award, USA, and the Distinguished Mexican Award.  \n© 2026 The Author(s) . Published by the Royal Society of Chemistry RSC Adv., 2026, 16, 27593–27609 | 27593  \nRSC Advances Review  \n1. Introduction  \nPoly ADP-ribose polymerase (PARP) is a family of nuclear enzymes that catalyse the poly(ADP-ribosyl)ation process, playing a cen","cbCaibsLUL5rpOOX","https://ap.wps.com/l/cbCaibsLUL5rpOOX","pdf",2441585,17,"English","# 1. Introduction","[{\"question\":\"How many marketed PARP inhibitors are discussed, and which ones are named?\",\"answer\":\"Seven marketed PARP inhibitors are named: olaparib, rucaparib, niraparib, talazoparib, fuzuloparib, pamiparib, and senaparib.\"},{\"question\":\"What change in synthetic strategy is highlighted over the past decade?\",\"answer\":\"Synthetic strategies have moved from step-intensive medicinal chemistry routes toward more streamlined, industrially viable processes.\"},{\"question\":\"Which key chemical transformations are described as part of modern manufacturing approaches?\",\"answer\":\"The review highlights transformations such as amide bond formation, C–H activation, carbopalladation, heterocycle construction, and stereocontrolled cyclisation.\"}]","Advancements in the manufacturing routes for the synthesis of marketed PARP inhibitors | PDF",1790120746,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7275474464133e62243fbc7a369f2205.webp",983,1287,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7587504f771f949db44610d7d36b58e3.webp",982,1286,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa35ab8ccf725ac97f97da25544ea140.webp",981,1284,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b38f304760d156ab753fe46a815d04b0.webp",980,1283]